NCT02567435 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 156
- group Id
- BG001
- value
- 156
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 325
- units
- Participants
- groups
- description
- Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37. Patients also undergo primary site RT beginning at week 13 or metastatic site RT beginning at week 43 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
- id
- BG000
- title
- Regimen A (VAC/VI)
- description
- Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37 and temsirolimus IV over 30-60 minutes on day 1 of weeks 1-12 and 21-42. Patients also undergo RT as in Regimen A. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
- id
- BG001
- title
- Regimen B (VAC/VI/Temsirolimus)
- description
- Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-10 and 13-22, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, and 22, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 4, 7, and 10. Patients undergo RT beginning at week 13 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
- id
- BG002
- title
- Regimen C (FOXO1 Fusion Negative, VAC/VA)
- description
- Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37 and temsirolimus IV over 30-60 minutes on day 1 of weeks 1-12 and 21-42. Patients also undergo RT as in Regimen A. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
- id
- BG003
- title
- Feasibility (VAC/VI/Temsirolimus)
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 145
- group Id
- BG001
- value
- 140
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 298
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 27
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 0.04
- upper Limit
- 35.84
- value
- 6.57
- group Id
- BG001
- lower Limit
- 0.35
- upper Limit
- 32.91
- value
- 6.05
- group Id
- BG002
- lower Limit
- 3.18
- upper Limit
- 6.58
- value
- 5.71
- group Id
- BG003
- lower Limit
- 0.17
- upper Limit
- 14.37
- value
- 4.59
- group Id
- BG004
- lower Limit
- 0.04
- upper Limit
- 35.84
- value
- 6.34
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 71
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 129
- title
- Female
- measurements
- group Id
- BG000
- value
- 85
- group Id
- BG001
- value
- 101
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 196
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 29
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 49
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 113
- group Id
- BG001
- value
- 117
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 240
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 36
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 9
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 37
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 99
- group Id
- BG001
- value
- 106
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 215
- title
- White
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 7
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 27
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 54
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 141
- group Id
- BG001
- value
- 135
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 289
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 17
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 15
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 4
- title
- New Zealand
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 156
- group Id
- BG001
- value
- 156
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 325
- units
- Participants
- groups
- description
- Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37. Patients also undergo primary site RT beginning at week 13 or metastatic site RT beginning at week 43 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
- id
- BG000
- title
- Regimen A (VAC/VI)
- description
- Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37 and temsirolimus IV over 30-60 minutes on day 1 of weeks 1-12 and 21-42. Patients also undergo RT as in Regimen A. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
- id
- BG001
- title
- Regimen B (VAC/VI/Temsirolimus)
- description
- Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-10 and 13-22, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, and 22, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 4, 7, and 10. Patients undergo RT beginning at week 13 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
- id
- BG002
- title
- Regimen C (FOXO1 Fusion Negative, VAC/VA)
- description
- Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37 and temsirolimus IV over 30-60 minutes on day 1 of weeks 1-12 and 21-42. Patients also undergo RT as in Regimen A. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
- id
- BG003
- title
- Feasibility (VAC/VI/Temsirolimus)
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 145
- group Id
- BG001
- value
- 140
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 298
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 27
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 0.04
- upper Limit
- 35.84
- value
- 6.57
- group Id
- BG001
- lower Limit
- 0.35
- upper Limit
- 32.91
- value
- 6.05
- group Id
- BG002
- lower Limit
- 3.18
- upper Limit
- 6.58
- value
- 5.71
- group Id
- BG003
- lower Limit
- 0.17
- upper Limit
- 14.37
- value
- 4.59
- group Id
- BG004
- lower Limit
- 0.04
- upper Limit
- 35.84
- value
- 6.34
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 71
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 129
- title
- Female
- measurements
- group Id
- BG000
- value
- 85
- group Id
- BG001
- value
- 101
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 196
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 29
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 49
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 113
- group Id
- BG001
- value
- 117
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 240
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 36
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 9
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 37
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 99
- group Id
- BG001
- value
- 106
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 215
- title
- White
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 7
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 27
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 54
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 141
- group Id
- BG001
- value
- 135
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 289
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 17
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 15
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 4
- title
- New Zealand
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle